Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:OKUR

OnKure Therapeutics 8/12/2025 Earnings Report

OnKure Therapeutics logo
$4.20 -0.32 (-6.97%)
As of 10:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

OnKure Therapeutics EPS Results

Actual EPS
-$1.14
Consensus EPS
-$1.23
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

OnKure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OnKure Therapeutics Announcement Details

Quarter
Date
8/12/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OnKure Therapeutics Earnings Headlines

OnKure Therapeutics Reports First Quarter 2026 Financial Results
May 5 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288243/0/en/onkure-therapeutics-reports-first-quarter-2026-financial-results.html
OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Tuesday
May 3 at 5:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30756267
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
The media's calling it "the biggest IPO in Wall Street history." But I'm not buying it. Institutions got into SpaceX at a $36 billion valuation years ago. By the time retail investors can buy shares, it'll be valued at $200 billion or more. They made 5-10x. You get the scraps. But what if I told you there's an entire asset class where this game is flipped? Where YOU can get in at the same prices institutions pay… before assets hit mainstream exchanges at 10-100x higher?tc pixel
May 6 at 1:00 AM  |  Decentralized Masters (Ad)
OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/onkure-therapeutics-okur-price-target-decreased-by-15-13-to-20-60/ar-AA21TxOx
OnKure Therapeutics (OKUR) Gets a Buy from JonesTrading
April 26, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OKUR/pressreleases/1185296/onkure-therapeutics-okur-gets-a-buy-from-jonestrading/
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and ...
March 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/onkure-therapeutics-announces-oversubscribed-150-120000760.html
See More OnKure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email.

About OnKure Therapeutics

OnKure Therapeutics (NASDAQ:OKUR) (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors. OKI-179 is designed to achieve potent antitumor activity while minimizing the off-target toxicities associated with earlier HDAC inhibitors. In parallel, OnKure is developing OKI-272, a reversible Bruton’s tyrosine kinase (BTK) inhibitor targeting B-cell malignancies and autoimmune conditions, with ongoing preclinical and early clinical assessments.

Founded by a team experienced in drug discovery and clinical development, OnKure leverages integrated chemistry, biology, and translational science capabilities to move its pipeline forward. The company collaborates with specialized contract research organizations and academic centers to support its clinical programs and accelerate development timelines.

OnKure’s management team brings together industry veterans with extensive backgrounds in oncology drug development, clinical operations, and regulatory affairs. The company is committed to advancing its therapeutic candidates through clinical proof-of-concept and toward potential commercialization for patients with high unmet medical needs.

View OnKure Therapeutics Profile
Earnings Tools